DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Same active ingredient (semaglutide), different regulatory pathway. Brand: FDA-approved, $499/mo NovoCare direct. Compounded: not FDA-approved, $199/mo Hims, regulatory wind-down ongoing.
Same active ingredient (semaglutide), different regulatory pathway. Brand: FDA-approved, $499/mo NovoCare direct. Compounded: not FDA-approved, $199/mo Hims, regulatory wind-down ongoing.
Both use semaglutide as the active ingredient. Differences: (1) Manufacturing — brand made by Novo Nordisk; compounded by 503A pharmacies. (2) Regulatory status — brand FDA-approved as Wegovy/Ozempic; compounded NOT FDA-approved as Wegovy equivalent. (3) Sterility/QC — brand has GMP requirements; compounded varies by pharmacy partner. (4) Cost — brand $1,349 retail, $499 NovoCare direct, $25 с savings card; compounded $199/mo Hims. (5) Future — compounded faces 60-day wind-down after FDA shortage resolution (Oct 2024). Bottom line: compounded as bridge if uninsured; transition к brand когда possible.